Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant PD-1 Antibody + Chemo in Stage IIIA-N2 NSCLC
NCT04422392Phase 2Terminated
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Jul 2020
- Primary completion
- Sep 2022
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Progression-Free Survival at 24 months. Started Jul 2020; status: terminated.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04422392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04422392.